Phase III trial of Emtriva shows continued response through 60 weeks.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      GILEAD Sciences Inc. 185049848 GILD
    • Abstract:
      Announces the efficacy of the nucleoside reverse transcriptase inhibitor for HIV know as Emtriva, developed by Gilead Sciences Inc. Potency of Emtriva in suppressing virus replication; Side effects associated with Emtriva; Dose of Emtriva administered to patient during the study.